Actinium Pharmaceuticals (ATNM) Financials

Actinium Pharmaceuticals (NYSE:ATNM) reported a significant improvement in its Q2 2026 income statement. Revenue reached $35.0 million, compared with no revenue in Q1 2026 and Q2 2025. With no reported cost of revenue, gross profit also totaled $35.0 million. The company generated $27.9 million of net income, or $0.89 per diluted share, compared with a $5.5 million loss, or $(0.18) per share, in Q1 2026.

The latest quarterly profit appears to reflect a major revenue-recognition event rather than a steady operating trend. ATNM’s noncurrent deferred revenue balance declined from $35.0 million in Q1 2026 to zero in Q2, while reported revenue increased by the same amount. Investors should determine whether this revenue is recurring, milestone-based or otherwise nonrecurring before extrapolating the Q2 results.

Operating expenses have generally improved from 2024 levels. Q2 2026 selling, general and administrative expense was $2.1 million, down from $3.6 million in Q2 2024, while research and development expense was $5.4 million, compared with $8.8 million during Q2 2024. However, ATNM remains dependent on product, licensing or milestone revenue because it recorded operating losses in every quarter presented before Q2 2026.

Cash flow remains a key concern. ATNM used $5.2 million in operating cash during Q2 2026 despite reporting $27.9 million of net income. The difference was driven primarily by a $33.4 million unfavorable change in operating assets and liabilities. Cash and equivalents declined from $42.1 million at March 31, 2026, to $36.5 million at June 30, 2026. The company also recorded negative operating cash flow in each quarter provided from Q3 2023 through Q2 2026.

The balance sheet improved substantially in Q2 2026. Total equity increased to $30.3 million from $2.3 million in Q1, largely because of the reported quarterly profit and the reduction in deferred revenue. Total liabilities declined to $9.9 million from $43.1 million. Nevertheless, accumulated retained earnings remained deeply negative at $(387.3) million, reflecting the company’s long history of losses.

• Revenue inflection: Q2 2026 revenue of $35.0 million was the first material quarterly revenue in the provided period and drove a $27.9 million net profit.
• Lower operating expenses: Q2 2026 operating expenses of $7.4 million were below the $12.4 million reported in Q2 2024 and close to the $7.5 million reported in Q2 2025.
• Improved capitalization: Total equity rose to $30.3 million, while total liabilities fell to $9.9 million in Q2 2026.
• Strong current liquidity: ATNM held $37.7 million of current assets against $9.3 million of current liabilities at June 30, 2026, implying a current ratio of approximately 4.1.
• Revenue quality requires monitoring: The Q2 revenue increase matched the elimination of $35.0 million of deferred revenue, so the sustainability and timing of future revenue remain uncertain.
• Cash flow did not match earnings: The company reported substantial accounting profit but negative operating cash flow because of working-capital changes.
• Interest income has helped reduce losses: Quarterly interest and investment income generally ranged from approximately $336,000 to $1.1 million, but it has not historically offset operating expenses.
• Persistent cash burn: Operating cash flow was negative in every quarter supplied, including $(5.2) million in Q2 2026.
• Declining cash reserves: Cash fell from $86.0 million in Q2 2024 to $36.5 million in Q2 2026, a decline of roughly 58%.
• Financing and dilution risk: ATNM has historically relied on common-equity issuance, and weighted-average shares increased from 27.9 million in Q1 2024 to 31.4 million in Q2 2026.